Deferred Income

12 Months Ended

Dec. 31, 2025

Deferred Income

Deferred Income

14. Deferred Income

The following table summarizes details of deferred income at December 31, 2025 and December 31, 2024. The nature of the deferred income relating to Lilly is described in Note 16. The nature of the deferred income relating to RSRT is described in Note 25.


		December 31,		December 31,
		2025		2024

		(€ in thousands)
Payments from Eli Lilly and Company		38,946		50,930
Payments from Rett Syndrome Research Trust		—		441
Total		38,946		51,371
Current portion		17,552		21,942
Total non-current portion		21,394		29,429

The current portion of deferred income reflects the estimated value of the Company’s work under the Lilly collaboration and RSRT grant that is expected to be performed within one year after the balance sheet date.

The table below analyzes ProQR’s undiscounted deferred income release based on estimates for the measure of progress and allocated into relevant maturity groupings until the contractual maturity date:


		Within		Between 1		Between 2
		1 year		and 2 years		and 5 years		Over 5 years

		(€ in thousands)
At December 31, 2025
Deferred Income		17,552		13,698		7,696		—
Total		17,552		13,698		7,696		—

At December 31, 2024
Deferred Income		21,942		21,087		8,342		—
Total		21,942		21,087		8,342		—